Zelnorm from Canadian Pharmacy
Between February and March 2007, Novartis reported the results of an analysis of 29 Zelnorm studies. In March 2007, tamiflu Novartis agreed to voluntarily suspend sales of Zelnorm following reports of adverse side effects such as heart attack and stroke and withdrew Zelnorm from the market. ( zelnorm )
